FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華潤醫藥集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 不適用 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 FF301 (A). 股份期權（根據發行人的股份期權計劃） II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號(如上市) | 03320 | | 說明 | | | | | | | | 股份期權計劃詳情 | 上月底結存的股份期權數 | | 本月內變動 | | 本月底結存的股份期權數 | 本月內因此發行的新股數 | 本月内因此自庫存轉讓的 | 本月底因此可能發行或自 | 本月底可於 ...

Core Viewpoint - China Resources Pharmaceutical announced the establishment of a 500 million yuan fund focused on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane (600062) and China Resources Pharmaceutical Investment as limited partners [1] - China Resources Pharmaceutical Group plans to invest 123 million yuan, accounting for approximately 24.6% of the total fund size [1] - Shenzhen China Resources Capital will act as the fund manager [1] Group 2: Strategic Goals - The establishment of the fund aligns with the group's strategic direction in synthetic biology, aiming to build an industrialization platform in Hohhot [1] - The fund is expected to enhance investment channels, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - Once established, the fund will be recorded as equity investment in the company's consolidated financial statements [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced the establishment of a proposed fund with a scale of RMB 500 million, focusing on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1 - The fund will be established through a limited partnership agreement involving China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners [1] - The total commitment from the group will be RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1]

Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane and China Resources Pharmaceutical Investment as limited partners, all of which are subsidiaries of the company [1] - The total commitment from the group will be RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic development direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key related areas [1] - The fund is expected to enhance investment channels in the synthetic biology industry, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1]

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced the establishment of a proposed fund with a scale of RMB 500 million, focusing on investments in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established through a limited partnership agreement involving China Resources Pharmaceutical (Shantou) as the general partner, China Resources Double Crane as a limited partner, and China Resources Pharmaceutical Investment as a limited partner [1] - The total commitment from the group will be RMB 123 million, representing approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Investment Focus - The fund aims to invest primarily in high-growth enterprises within the fields of synthetic biology, innovative drugs, and biotechnology [1]

Core Viewpoint - China Resources Pharmaceutical (03320) has established a limited partnership agreement to create a proposed fund of RMB 500 million, focusing on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with contributions from China Resources Pharmaceutical (Shantou) as the general partner, China Resources Double Crane as a limited partner, and China Resources Pharmaceutical Investment as a limited partner, all of which are subsidiaries of the company [1] - The total commitment from the group is RMB 123 million, accounting for approximately 24.6% of the total fund commitment [1] - Shenzhen China Resources Capital will be appointed as the fund manager [1] Group 2: Strategic Objectives - Establishing the fund aligns with the company's strategic direction in synthetic biology [1] - The group aims to build a synthetic biology industrialization platform in Hohhot, optimizing its strategic layout in key areas [1] - The fund is expected to enhance investment channels in synthetic biology, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - After the fund is established, it will be accounted for as equity investment in the company's consolidated financial statements [1]

（股份代號：3320） 關連交易 成立基金 董事會欣然宣佈，於二零二五年十月二十九日，華潤醫藥（汕頭）（作為普通 合夥人）、華潤雙鶴（作為有限合夥人）以及華潤醫藥投資（作為有限合夥人） （各自為本公司之附屬公司）與其他合夥人就成立擬議規模為人民幣5億元 之基金訂立有限合夥協議。基金將主要從事合成生物學、創新藥物及生物技 術領域的高增長企業投資。本集團擬承諾出資總額將為人民幣1.23億元，約 佔基金承諾出資總額的24.6%。基金於成立後將不會入賬為本公司之附屬公 司。深圳華潤資本將獲委託為基金之基金管理人。 於本公告之日，一名合夥人漢威華酉汕頭為華潤投資（天津）的全資附屬公 司，而華潤投資（天津）由本公司控股股東華潤集團最終持有。因此，漢威華 酉汕頭構成了本公司的關連人士，而有限合夥協議和其項下擬進行的交易 構成本公司於上市規則第14A章項下的關連交易。 1 由於上市規則第14.07條項下有關成立基金的一項或多項適用百分比率超過 0.1%但均低於5%，故根據上市規則第14A章，有限合夥協議及其項下擬進行 的交易僅須遵守申報及公告規定，惟獲豁免遵守獨立股東批准規定。 香港交易及結算所有限公司及香港聯合交易所有限公 ...

Core Viewpoint - China Resources Pharmaceutical (03320) announced that its subsidiary, China Resources Boya Bio (300294), achieved a total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, representing a year-on-year growth of 18.4%. However, the net profit was 343 million RMB, showing a year-on-year decline of 16.8% [1] Summary by Category - **Revenue Performance** - China Resources Boya Bio reported total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, which is an increase of 18.4% compared to the previous year [1] - **Profitability** - The net profit for the same period was 343 million RMB, reflecting a decrease of 16.8% year-on-year [1]

Group 1 - The core viewpoint of the article highlights the financial performance of China Resources Pharmaceutical's subsidiary, China Resources Boya Biopharmaceutical, for the nine months ending September 30, 2025, showing a revenue increase but a decline in net profit [1] Group 2 - The company's operating revenue reached approximately RMB 1.474 billion, representing a year-on-year growth of 18.4% [1] - The net profit for the same period was approximately RMB 343 million, reflecting a year-on-year decrease of 16.8% [1]

Group 1 - The core point of the article is that China Resources Pharmaceutical announced its subsidiary, China Resources Boya Biopharmaceutical, achieved total operating revenue of 1.474 billion RMB for the nine months ending September 30, 2025, representing a year-on-year growth of 18.4% [1] - The net profit for the same period was 343 million RMB, which reflects a year-on-year decline of 16.8% [1]